Janux Therapeutics, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Janux Therapeutics, Inc. (JANX) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$21.97 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-06
- Janux Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$21.97M.
- Janux Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$24.36M.
- Janux Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$31.95M.
- Janux Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$24.31M.
- Janux Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$63.06M.
- Janux Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was -$32.67M.
- Janux Therapeutics, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$6.78M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$21.97M 10-Q · filed 2026-08-06 | -$46.33M 10-Q · filed 2026-08-06 | -$78.28M derived: sum of 3 quarters · filed 2026-08-06 | -$102.60M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | -$24.36M 10-Q · filed 2026-05-07 | -$56.31M derived: sum of 2 quarters · filed 2026-05-07 | -$80.63M derived: sum of 3 quarters · filed 2026-05-07 | -$114.48M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$31.95M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-28 | -$56.26M derived: sum of 2 quarters · filed 2026-04-28 | -$90.12M derived: sum of 3 quarters · filed 2026-08-06 | -$113.63M DEF 14A · filed 2026-04-28 | -$113.63M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$24.31M 10-Q · filed 2025-11-06 | -$58.17M derived: sum of 2 quarters · filed 2026-08-06 | -$81.68M 10-Q · filed 2025-11-06 | -$101.89M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$33.86M 10-Q · filed 2026-08-06 | -$57.37M 10-Q · filed 2026-08-06 | -$77.58M derived: sum of 3 quarters · filed 2026-08-06 | -$105.64M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$23.51M 10-Q · filed 2026-05-07 | -$43.72M derived: sum of 2 quarters · filed 2026-05-07 | -$71.78M derived: sum of 3 quarters · filed 2026-05-07 | -$77.74M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$20.21M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-28 | -$48.27M derived: sum of 2 quarters · filed 2026-04-28 | -$54.23M derived: sum of 3 quarters · filed 2026-04-28 | -$68.99M DEF 14A · filed 2026-04-28 | -$68.99M 10-K · filed 2025-02-27 |
| 2024-09-30 | -$28.06M 10-Q · filed 2025-11-06 | -$34.02M derived: sum of 2 quarters · filed 2025-11-06 | -$48.78M 10-Q · filed 2025-11-06 | -$60.53M derived: sum of 4 quarters · filed 2026-04-28 | |
| 2024-06-30 | -$5.96M 10-Q · filed 2025-08-07 | -$20.72M 10-Q · filed 2025-08-07 | -$32.47M derived: sum of 3 quarters · filed 2026-04-28 | -$44.04M derived: sum of 4 quarters · filed 2026-04-28 | |
| 2024-03-31 | -$14.76M 10-Q · filed 2025-05-08 | -$26.52M derived: sum of 2 quarters · filed 2026-04-28 | -$38.08M derived: sum of 3 quarters · filed 2026-04-28 | -$55.59M derived: sum of 4 quarters · filed 2026-04-28 | |
| 2023-12-31 | -$11.76M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-28 | -$23.32M derived: sum of 2 quarters · filed 2026-04-28 | -$40.83M derived: sum of 3 quarters · filed 2026-04-28 | -$58.29M DEF 14A · filed 2026-04-28 | -$58.29M 10-K · filed 2024-03-08 |
| 2023-09-30 | -$11.57M 10-Q · filed 2024-11-06 | -$29.08M derived: sum of 2 quarters · filed 2024-11-06 | -$46.53M 10-Q · filed 2024-11-06 | -$62.60M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | -$17.51M 10-Q · filed 2024-08-07 | -$34.97M 10-Q · filed 2024-08-07 | -$51.03M derived: sum of 3 quarters · filed 2025-02-27 | -$67.73M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | -$17.46M 10-Q · filed 2024-05-08 | -$33.52M derived: sum of 2 quarters · filed 2025-02-27 | -$50.22M derived: sum of 3 quarters · filed 2025-02-27 | -$67.11M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | -$16.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$32.76M derived: sum of 2 quarters · filed 2025-02-27 | -$49.65M derived: sum of 3 quarters · filed 2025-02-27 | -$63.06M 10-K · filed 2025-02-27 | |
| 2022-09-30 | -$16.70M 10-Q · filed 2023-11-07 | -$33.58M derived: sum of 2 quarters · filed 2023-11-07 | -$46.99M 10-Q · filed 2023-11-07 | -$60.41M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | -$16.89M 10-Q · filed 2023-08-08 | -$30.30M 10-Q · filed 2023-08-08 | -$43.71M derived: sum of 3 quarters · filed 2023-08-08 | -$54.48M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | -$13.41M 10-Q · filed 2023-05-09 | -$26.83M derived: sum of 2 quarters · filed 2023-05-09 | -$37.59M derived: sum of 3 quarters · filed 2023-05-09 | -$43.80M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | -$13.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | -$24.18M derived: sum of 2 quarters · filed 2023-03-10 | -$30.39M derived: sum of 3 quarters · filed 2023-03-10 | -$32.67M 10-K · filed 2023-03-10 | |
| 2021-09-30 | -$10.77M 10-Q · filed 2022-11-10 | -$16.97M derived: sum of 2 quarters · filed 2022-11-10 | -$19.26M 10-Q · filed 2022-11-10 | -$20.91M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$6.21M 10-Q · filed 2022-08-09 | -$8.49M 10-Q · filed 2022-08-09 | -$10.14M derived: sum of 3 quarters · filed 2022-08-09 | -$11.40M derived: sum of 4 quarters · filed 2022-08-09 | |
| 2021-03-31 | -$2.28M 10-Q · filed 2022-05-10 | -$3.94M derived: sum of 2 quarters · filed 2022-05-10 | -$5.20M derived: sum of 3 quarters · filed 2022-05-10 | -$7.66M derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | -$2.91M derived: sum of 2 quarters · filed 2022-03-18 | -$5.37M derived: sum of 3 quarters · filed 2022-03-18 | -$6.78M 10-K · filed 2022-03-18 | |
| 2020-09-30 | -$1.26M 10-Q · filed 2021-11-09 | -$3.72M derived: sum of 2 quarters · filed 2021-11-09 | -$5.13M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | -$2.46M 10-Q · filed 2021-08-10 | -$3.87M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |